4SC Resminostat – a novel epigenetic therapy to treat solid cancers in advanced clinical development video

Bit Index AI |

Broadcast Live | Upload & Publish |

About |

Close [ x ]

Forgotten Password?

You need to install or upgrade your Flash Player!

3B NEXUS video platform & portal supports the latest version of Macromedia Flash player.

3B PLAYER by 3B NEXUS

Close [ X ]

Copy this code to embed & stream this video on your website

<div id="svp_player1120720" style="width:636px;height:342px;"><strong>You need to install or upgrade your Flash Player!</strong><br><a href="http://www.macromedia.com/go/getflashplayer" target="_new"><img src="../../img/flash_link.gif" border="0" width="88" height="31"/></a>
	<p>3B NEXUS video platform & portal supports the latest version of  <a href="http://www.macromedia.com/go/getflashplayer" target="_new">Macromedia Flash</a> player.</p> 
	<hr/> <center><h3>3B PLAYER by <a href="/">3B NEXUS</a></center></div>
	<script language="JavaScript">
svp_clip_id = "1120720";
nexus_user_id = "";
svp_player_color1 = "#3399FF";
svp_player_color = "#010101";
svp_player_color_ratio = 1.0;
svp_player_height = "342";
svp_player_width = "636";
svp_transparent = "true";
svp_pause="1";
svp_stretch_video=1;
svp_start_volume="15";
svp_bg_color="#FFFFFF";
svp_fs_mode="2";
svp_no_fullscreen="0";
svp_no_controls="";
svp_auto_hide="1";
svp_skin="2";
svp_start_img="0";
svp_use_div="svp_player1120720";
</script>
<script language="JavaScript" type="text/javascript" src="../../js/eplayer.js"></script>

Copy this URL to share or create a link back to this video

4SC AG (VSC)

Dr. Ulrich Dauer

Chief Executive Officer

Germany

4SC Resminostat – a novel epigenetic therapy to treat solid cancers in advanced clinical development

Resminostat, recently met the primary endpoint in a Phase II study in advanced liver cancer. The therapy mediates tumour cell “resensitisation” with a novel epigenetic mode of action. Resensitisation can suppress or reverse drug tolerance mechanisms that tumour cells can develop against cancer drugs. The supplementary administration of resminostat can enable the effective treatment of patients with cancer drugs to which patient response is no longer adequate.

Visit Website Disclaimer View Channel Factsheet Presentation Press Release

Please select a Media Channel	[ close ]
Please select the appropriate option to comply with legal regulations

Individual Investor

Professional Investor or Financial Advisor

This multimedia channel includes videos, webcasts and live broadcasts suitable for members of the general public over 18 years of age and not engaged in providing investment advice. Access this channel for personal interest & information only.

This multimedia channel includes investor videos and webcast presentations, live broadcasts and documents intended only for authorised and regulated professionals and financial advisers eligible to provide investment advice to private investors.

* I comply with these terms

Remember my choice for all channels on this portal

Enter Media Channel »

No reliance should be placed on the information on this site which may change without notice.

You should read the Terms & Conditions section before browsing this site.